Table 5.
Antibiotic susceptibilities of 32 MRSA isolates, stratified by CA-MRSA criteria
| Antibiotic | No. (%) of samples, by susceptibility | ||
|---|---|---|---|
| Epidemiological classification | |||
| CA-MRSA (n = 22) | Non CA-MRSA (n = 10) | P-value | |
| Chloramphenicol (%) | 12 (54.5) | 7 (70) | 0.467 |
| Clindamycin (%)a | 4 (19) | 0 (0) | 0.287 |
| Erythromycin (%) | 4 (18.2) | 0 (0) | 0.283 |
| Minocycline (%) | 20 (95.2) | 8 (80) | 0.237 |
| Levofloxacin (%) | 18 (81.8) | 5 (50) | 0.096 |
| Rifampin (%) | 22 (100) | 8 (80) | 0.091 |
| TMP-SMX (%) | 21 (95.5) | 7 (70) | 0.079 |
| Vancomycin (%) | 22 (100) | 10 (100) | 1.000 |
Data are number (%) of patients, unless otherwise indicated
TMP-SMX trimethoprim-sulfamethoxazole
aSusceptibility to clindamycin was determined for 21 CA-MRSA isolates and nine non-CA-MRSA isolates. The D-test was performed to detect inducible clindamycin resistance for isolates found to be resistant to erythromycin, but susceptible to clindamycin